These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 26259734)

  • 1. Regulation of human glia by multiple sclerosis disease modifying therapies.
    Healy LM; Michell-Robinson MA; Antel JP
    Semin Immunopathol; 2015 Nov; 37(6):639-49. PubMed ID: 26259734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Central nervous system effects of current and emerging multiple sclerosis-directed immuno-therapies.
    Antel JP; Miron VE
    Clin Neurol Neurosurg; 2008 Nov; 110(9):951-7. PubMed ID: 18502570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune cell trafficking across the barriers of the central nervous system in multiple sclerosis and stroke.
    Lopes Pinheiro MA; Kooij G; Mizee MR; Kamermans A; Enzmann G; Lyck R; Schwaninger M; Engelhardt B; de Vries HE
    Biochim Biophys Acta; 2016 Mar; 1862(3):461-71. PubMed ID: 26527183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis.
    Cohen JA; Chun J
    Ann Neurol; 2011 May; 69(5):759-77. PubMed ID: 21520239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
    Wingerchuk DM; Carter JL
    Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Role of Astrocytes in Multiple Sclerosis.
    Ponath G; Park C; Pitt D
    Front Immunol; 2018; 9():217. PubMed ID: 29515568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Direct Effects of Fingolimod in the Central Nervous System: Implications for Relapsing Multiple Sclerosis.
    Hunter SF; Bowen JD; Reder AT
    CNS Drugs; 2016 Feb; 30(2):135-47. PubMed ID: 26715391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Central nervous system-directed effects of FTY720 (fingolimod).
    Miron VE; Schubart A; Antel JP
    J Neurol Sci; 2008 Nov; 274(1-2):13-7. PubMed ID: 18678377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distribution of the immune inhibitory molecules CD200 and CD200R in the normal central nervous system and multiple sclerosis lesions suggests neuron-glia and glia-glia interactions.
    Koning N; Swaab DF; Hoek RM; Huitinga I
    J Neuropathol Exp Neurol; 2009 Feb; 68(2):159-67. PubMed ID: 19151626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibodies to lymphotoxin alpha (LT alpha) and LT beta recognize different glial cell types in the central nervous system.
    Cannella B; Sizing ID; Benjamin CD; Browning JL; Raine CS
    J Neuroimmunol; 1997 Sep; 78(1-2):172-9. PubMed ID: 9307242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of glial cell activation ameliorates the severity of experimental autoimmune encephalomyelitis.
    Guo X; Nakamura K; Kohyama K; Harada C; Behanna HA; Watterson DM; Matsumoto Y; Harada T
    Neurosci Res; 2007 Dec; 59(4):457-66. PubMed ID: 17920148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current disease-modifying therapies in multiple sclerosis.
    Kieseier BC; Hartung HP
    Semin Neurol; 2003 Jun; 23(2):133-46. PubMed ID: 12894379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of interferon-beta on oligodendroglial cells.
    Heine S; Ebnet J; Maysami S; Stangel M
    J Neuroimmunol; 2006 Aug; 177(1-2):173-80. PubMed ID: 16753226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Currently approved and emerging oral therapies in multiple sclerosis: An update for the ophthalmologist.
    Eckstein C; Bhatti MT
    Surv Ophthalmol; 2016; 61(3):318-32. PubMed ID: 26703886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct and indirect effects of immune and central nervous system-resident cells on human oligodendrocyte progenitor cell differentiation.
    Moore CS; Cui QL; Warsi NM; Durafourt BA; Zorko N; Owen DR; Antel JP; Bar-Or A
    J Immunol; 2015 Jan; 194(2):761-72. PubMed ID: 25505283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon beta promotes nerve growth factor secretion early in the course of multiple sclerosis.
    Biernacki K; Antel JP; Blain M; Narayanan S; Arnold DL; Prat A
    Arch Neurol; 2005 Apr; 62(4):563-8. PubMed ID: 15824253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Current treatment of multiple sclerosis].
    Csépány T
    Lege Artis Med; 2011 Feb; 21(2):97-104. PubMed ID: 21710707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role for CXCR2 and CXCL1 on glia in multiple sclerosis.
    Omari KM; John G; Lango R; Raine CS
    Glia; 2006 Jan; 53(1):24-31. PubMed ID: 16086366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Established and novel disease-modifying treatments in multiple sclerosis.
    Cross AH; Naismith RT
    J Intern Med; 2014 Apr; 275(4):350-63. PubMed ID: 24444048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel Agents for Relapsing Forms of Multiple Sclerosis.
    Straus Farber R; Harel A; Lublin F
    Annu Rev Med; 2016; 67():309-21. PubMed ID: 26394285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.